From the Research
Cuvitra injection power should be administered at a dose of 600,000 IU intramuscularly to effectively increase serum 25-hydroxyvitamin D levels without evidence of metabolic abnormality, as supported by the study published in the Journal of AOAC International 1. The Cuvitra injection is used to treat vitamin D deficiency, which is defined as a 25-hydroxyvitamin D level <50 nM.
- The study found that intramuscular injection of a large bolus of vitamin D effectively increases serum 25-hydroxyvitamin D levels without evidence of metabolic abnormality.
- The optimal dose of Cuvitra injection power is 600,000 IU, as it provides long-lasting moderate increases in serum 25-hydroxyvitamin D levels and shorter-term changes in plasma calcium.
- The study also found that serum 25-hydroxyvitamin D levels increased at 3,4, and 24 weeks postinjection, peaking at 4 weeks, and generally remained <125 nM, the upper limit recommended by the U.S. Institute of Medicine. However, it's worth noting that other studies have also investigated the effectiveness of vitamin D supplementation, including a study published in the Endocrine Practice journal in 2020, which found that a single dose of 200,000 IU, 400,000 IU, or 600,000 IU intramuscular vitamin D2 raises total 25-hydroxyvitamin D levels by 5.0,7.0, or 10.3 ng/mL on average for at least 12 weeks and reduces intact parathyroid hormone levels without affecting levels of serum calcium, bone turnover markers, and vitamin D binding protein 2. Additionally, a study published in the Journal of the American Geriatrics Society in 1980 found that intramuscular rather than oral vitamin supplementation is a more effective method for maintaining adequate blood levels of vitamins in the elderly 3. Overall, the evidence suggests that Cuvitra injection power can be an effective treatment for vitamin D deficiency, and the optimal dose is 600,000 IU intramuscularly.